Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
일요일, 8월 23

Axsome Therapeutics Inc

AXSMNASDAQ
Trade with Public
Trade with Public
$207.77
-0.26-0.12%
가까이에: Aug 21, 5:00 PM EST
$207.77
N/A
시간외: Aug 21, 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Axsome Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Axsome Therapeutics (AXSM).

Price Target Range — 7 Quarters

Analyst Consensus — 20 Analysts

20Buy
Consensus RatingBuy# Analysts20Avg. Consensus PT$232Upside to Avg. PT+11.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026MizuhoGraig SuvannavejhPT RaiseOutperform$306→$316
Aug 11, 2026Morgan StanleySean LaamanPT RaiseEqual-Weight$242→$251
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $316

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $306 to $316.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $251

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $242 to $251.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $297

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $304 to $297.
Benzinga Newsdesk

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.
Avi Kapoor

PRO
Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $275

Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $260 to $275.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $256

Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target from $255 to $256.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved